Workshop 21
Vaccines

Programme

• 10:45 – 11:00 12 Min. 3 Min.

  • Abstract Talk
  • O 115

  MVA-HBVac – a novel vector for treatment of chronic hepatitis B via therapeutic vaccination

  • Dr. Anna Kosinska (Neuherberg / DE)

   Adaptive immunity, Vaccines
• 11:00 – 11:15 12 Min. 3 Min.

  • Abstract Talk
  • O 116

  An MCMV-based vaccine expressing full-length parental SARS-CoV-2 spike provides long-lived and broad protection against SARS-CoV-2 variants in mice

  • Dr. Henning Jacobsen (Braunschweig / DE)

   SARS-CoV-2, Vaccines
• 11:15 – 11:30 12 Min. 3 Min.

  • Abstract Talk
  • O 117

  Trivalent MVA-based vaccine candidate induces a potent immune response against Sudan Ebolavirus, Marburg and Lassa fever virus in guinea pigs

  • Dr. Martina Billmeier (Regensburg / DE)

   Vaccines, Viral vectors and gene therapy
• 11:30 – 11:45 12 Min. 3 Min.

  • Abstract Talk
  • O 118

  Rational design of a cell-permeable antigen presentation platform for needle-free vaccination

  • Jan Raupach (Langen / DE)

   Adaptive immunity, Vaccines
• 11:45 – 12:00 12 Min. 3 Min.

  • Abstract Talk
  • O 119

  Characterizing neutralization profiles after bivalent COVID-19 boosting using antigenic cartography

  • Annika Rössler (Innsbruck / AT)

   Vaccines
• 12:00 – 12:15 12 Min. 3 Min.

  • Abstract Talk
  • O 120

  Immune suppression of vaccine-induced CD8⁺ T-cell responses by gamma retrovirus envelope is mediated by interleukin-10-producing CD4⁺ T cells

  • PD Dr. Wibke Bayer (Essen / DE)

   Adaptive immunity, Vaccines